Angiomax Generics Imminent After Court Rules Patents Are Invalid
This article was originally published in The Pink Sheet Daily
Executive Summary
Exactly when The Medicine Co.'s top seller will see competition isn't clear – highlighting industry concerns with FDA review times for ANDAs. Hospira and Sagent have tentative approval and several other firms have pending applications.